Evidence map›Paper›PMID 42414553›Full record

ArticleEuropean journal of human genetics : EJHG2026

Confirmation of frameshift variants in the last exon of FGFR1 as a cause of multiple epiphyseal dysplasia.

Marion Aubert Mucca, Roberto Mendoza-Londono, Valérie Cormier-Daire, Thomas Edouard, Lucie Dupuis, Andrew W Howard, Olivier Patat, Hanna Faghfoury, Josh Silver, Renaud Touraine and 2 more

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Genomics cycle: discover, diagnose, interpret, act.European journal of human genetics : EJHG · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marion Aubert MuccaCentre Hospitalier Universitaire de Toulouse, Centre de compétence Anomalies du Développement (CLAD SOOR), Service de Génétique médicale, Toulouse, France.ORCID http://orcid.org/0000-0002-8638-2630
Roberto Mendoza-LondonoDivision of Clinical and Metabolic Genetics, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-3542-8106
Valérie Cormier-DaireDepartment of Genomic medicine for rare diseases, Inserm UMR 1163, Imagine Institute, Hôpital Necker-Enfants Malades, AP-HP, Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0002-2839-9856
Thomas EdouardEndocrine, Bone Diseases and Genetics Unit, Reference Center for Rare Diseases of Calcium and Phosphate Metabolism and Rare Bone Diseases, OSCAR Network, ERN BOND, Children's Hospital, Toulouse University Hospital, Toulouse, France.ORCID http://orcid.org/0000-0002-9222-5009
Lucie DupuisFred A. Litwin Family Centre in Genetic Medicine, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-6068-8199
Andrew W HowardDepartment of Surgery, University of Toronto, and the Department of Orthopedics, The Hospital for Sick Children, Toronto, ON, Canada.
Olivier PatatCentre Hospitalier Universitaire de Toulouse, Centre de compétence Anomalies du Développement (CLAD SOOR), Service de Génétique médicale, Toulouse, France.
Hanna FaghfouryDepartment of Medicine, University of Toronto, Toronto, ON, Canada.
Josh SilverFred A. Litwin Family Centre in Genetic Medicine, University Health Network, Toronto, ON, Canada.
Renaud TouraineCentre Hospitalier Universitaire de Saint-Étienne, Service de Génétique médicale, Saint-Étienne, France.
Philippe M CampeauCentre Hospitalier Universitaire Sainte-Justine, Département de pédiatrie, Université de Montréal, Montréal, QC, Canada.ORCID http://orcid.org/0000-0001-9713-7107
Alban ZieglerCentre Hospitalier Universitaire de Toulouse, Centre de compétence Anomalies du Développement (CLAD SOOR), Service de Génétique médicale, Toulouse, France. ziegler.a@chu-toulouse.fr.ORCID http://orcid.org/0000-0003-0287-3561

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple epiphyseal dysplasia (MED) is a genetically diverse skeletal disorder characterized by abnormal and delayed epiphyseal ossification, early-onset osteoarthritis, joint pain and mild short stature. MED is primarily caused by pathogenic variants in genes involved in cartilage and bone development, including COMP, MATN, COL9A1-3, CANT1 and SLC26A2. FGFR1 was suggested as a cause of MED in a study published in 2020, which reported a frameshift variant in the last exon of this gene. We assembled an international cohort of 13 individuals with MED carrying C-terminal frameshift variants in FGFR1 (NM_023110.3: c.2424_2425del, c.2436_2440del, and c.2460dup). In all three families, the frameshift variants are predicted to result in the same 164-amino acid C-terminal elongation tail. The cohort includes two families (three affected individuals in one, nine in the other) and one previously reported individual. All affected individuals presented with MED without vertebral involvement. Age of symptom onset ranged from 3 to 13 years, with complete penetrance. Genu valgum was very frequent, and most affected patients required its surgical correction. Hypogonadotropic hypogonadism was present in approximately half of the cases. Adult height was mildly reduced, with an median of 164.0 cm in males (-1.7 SDS) and 153.1 cm in females (-1.6 SDS). Structural modeling for the novel C-terminal stretch as a result of the variants could acquire secondary structures, including an α-helix and a β-sheet domain, and could bring a potential antimorphic effect. Our findings confirm FGFR1 C-terminal frameshift variants as a cause of MED and provide further clinical characterization of this disorder.

Indexed as

Frameshift MutationOsteochondrodysplasiasReceptor, Fibroblast Growth Factor, Type 1AdolescentAdultChildChild, PreschoolExonsFemaleHumansMalePedigreeFGFR1 protein, humanReceptor, Fibroblast Growth Factor, Type 1

Identifiers

PMID42414553
PMCPMC13634043

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.